Literature DB >> 9142121

Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination.

J D Boyer1, K E Ugen, B Wang, M Agadjanyan, L Gilbert, M L Bagarazzi, M Chattergoon, P Frost, A Javadian, W V Williams, Y Refaeli, R B Ciccarelli, D McCallus, L Coney, D B Weiner.   

Abstract

Novel approaches for the generation of more effective vaccines for HIV-1 are of significant importance. In this report we analyze the immunogenicity and efficacy of an HIV-1 DNA vaccine encoding env, rev and gag/pol in a chimpanzee model system. The immunized animals developed specific cellular and humoral immune responses. Animals were challenged with a heterologous chimpanzee titered stock of HIV-1 SF2 virus and followed for 48 weeks after challenge. Polymerase chain reaction coupled with reverse transcription (RT-PCR) results indicated infection in the control animal, whereas those animals vaccinated with the DNA constructs were protected from the establishment of infection. These studies serve as an important benchmark for the use of DNA vaccine technology for the production of protective immune responses.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9142121     DOI: 10.1038/nm0597-526

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  69 in total

1.  DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques.

Authors:  S Cherpelis; I Shrivastava; A Gettie; X Jin; D D Ho; S W Barnett; L Stamatatos
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques.

Authors:  P S Polacino; V Stallard; J E Klaniecki; S Pennathur; D C Montefiori; A J Langlois; B A Richardson; W R Morton; R E Benveniste; S L Hu
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

3.  Intralymphatic immunization enhances DNA vaccination.

Authors:  K J Maloy; I Erdmann; V Basch; S Sierro; T A Kramps; R M Zinkernagel; S Oehen; T M Kündig
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

Review 4.  AIDS vaccine development: let a thousand flowers bloom.

Authors:  J S Oxford; M Addawe; R Lambkin
Journal:  J Clin Pathol       Date:  1998-10       Impact factor: 3.411

5.  Vaccination with inactivated virus but not viral DNA reduces virus load following challenge with a heterologous and virulent isolate of feline immunodeficiency virus.

Authors:  M J Hosie; T Dunsford; D Klein; B J Willett; C Cannon; R Osborne; J Macdonald; N Spibey; N Mackay; O Jarrett; J C Neil
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

6.  Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer.

Authors:  S Zucchelli; S Capone; E Fattori; A Folgori; A Di Marco; D Casimiro; A J Simon; R Laufer; N La Monica; R Cortese; A Nicosia
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

7.  Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants.

Authors:  J J Kim; J S Yang; T C VanCott; D J Lee; K H Manson; M S Wyand; J D Boyer; K E Ugen; D B Weiner
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

Review 8.  Combination DNA plus protein HIV vaccines.

Authors:  Shan Lu
Journal:  Springer Semin Immunopathol       Date:  2006-09-21

Review 9.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

10.  A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity.

Authors:  Kenji Someya; Ke-Qin Xin; Kazuhiro Matsuo; Kenji Okuda; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.